2021
Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Frontiers In Surgery 2021, 8: 775527. PMID: 34888347, PMCID: PMC8649716, DOI: 10.3389/fsurg.2021.775527.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerInvasive bladder cancerOncological outcomesSafety profileBladder cancerAdverse eventsMeta-analysisBacillus Calmette-Guerin instillationsHigh-risk NMIBC patientsIntravesical bacillus Calmette-GuerinMeta-analysis of clinical studiesBCG maintenance therapySystematic reviewMonths recurrence rateCochrane RoB toolCertainty of evidenceRisk of biasComprehensive literature searchBCG shortageChemotherapy maintenanceNMIBC patientsBCG treatmentMaintenance therapyRecurrence rate1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
Zhao H, Chan V, Castellani D, Chan E, Ong W, Peng Q, Moschini M, Krajewski W, Pradere B, Ng C, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan W, Kelly J, Shariat S, Witjes J, Teoh J. 1459 Intravesical Chemohyperthermia Versus Bacillus Calmette-Guerin Instillation for Intermediate- And High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. British Journal Of Surgery 2021, 108: znab259.955. DOI: 10.1093/bjs/znab259.955.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerHigh-risk non-muscle invasive bladder cancerRecurrence-free survivalProgression-free survivalInvasive bladder cancerCarcinoma in situChemo-hyperthermiaAdverse eventsChemotherapy instillationSafety profileBladder cancerBCG groupBCG maintenance therapyTrans-urethral resectionMeta-analysisMonths recurrence rateSystematic reviewComprehensive literature searchQuality of evidenceBCG failureBCG shortageMaintenance therapyOncological outcomesRandomised controlled trialsRecurrence rateDelayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic
Chan V, Tan W, Leow J, Tan W, Ong W, Chiu P, Gurung P, Pirola G, Orecchia L, Liew M, Lee H, Wang Y, Chen I, Castellani D, Wroclawski M, Mayor N, Sathianathen N, Braga I, Liu Z, Moon D, Tikkinen K, Kamat A, Meng M, Ficarra V, Giannarini G, Teoh J. Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic. World Journal Of Urology 2021, 39: 4295-4303. PMID: 34031748, PMCID: PMC8143063, DOI: 10.1007/s00345-021-03734-1.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaLocalised RCCDelayed surgeryCytoreductive nephrectomyDeferred CNOverall survivalCell carcinomaTargeted therapyAssociated with worse cancer-specific survivalAssociated with better overall survivalT1a renal cell carcinomaEffect of delaying surgeryDeferred cytoreductive nephrectomyCancer-specific survivalMeta-analysisElective cancer surgeryNewcastle-Ottawa ScaleSystematic reviewComprehensive literature searchUpfront CNOncological effectivenessRisk of biasImmediate surgeryRandomised controlled trials
2019
PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis
Tan W, Tan W, Inman B. PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis. Bladder Cancer 2019, 5: 211-223. PMID: 31867425, PMCID: PMC6919639, DOI: 10.3233/blc-190238.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsProgression-free survivalMetastatic urothelial carcinomaImmune checkpoint inhibitor therapyProgrammed death-ligand 1Response ratePooled Kaplan-Meier analysisBiomarker statusHigher overall response rateAnalyzed response ratesMetastatic urothelial cancerDeath-ligand 1Programmed death-1Platinum-based chemotherapyPD-L1/PD-1Kaplan-Meier analysisMeta-analysisOverall response rateProportional hazards survival analysisSystematic reviewComprehensive literature searchCheckpoint inhibitorsDeath-1PD-1Platinum therapy